210 related articles for article (PubMed ID: 36893518)
1. Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis.
Palazzo A; Ciccarese C; Iacovelli R; Cannizzaro MC; Stefani A; Salvatore L; Bria E; Tortora G
ESMO Open; 2023 Apr; 8(2):101154. PubMed ID: 36893518
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
4. Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials.
Castellano G; Corti C; Boldrini L; Gervaso L; Criscitiello C; Curigliano G
Cancer Treat Rev; 2023 Sep; 119():102601. PubMed ID: 37473517
[TBL] [Abstract][Full Text] [Related]
5. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
Nitecki R; Melamed A; Gockley AA; Floyd J; Krause KJ; Coleman RL; Matulonis UA; Giordano SH; Lu KH; Rauh-Hain JA
Gynecol Oncol; 2021 Jun; 161(3):653-659. PubMed ID: 33736856
[TBL] [Abstract][Full Text] [Related]
6. Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.
Rizzo A; Mollica V; Merler S; Morelli F; Sorgentoni G; Oderda M; Santoni M; Massari F
Expert Opin Drug Metab Toxicol; 2022 Mar; 18(3):235-240. PubMed ID: 35485878
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM; Leary A; Dolladille C; Chrétien B; Poulain L; González-Martín A; Moore K; O'Reilly EM; Ray-Coquard I; Alexandre J
Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Hao J; Liu Y; Zhang T; He J; Zhao H; An R; Xue Y
Crit Rev Oncol Hematol; 2021 Jan; 157():103145. PubMed ID: 33254040
[TBL] [Abstract][Full Text] [Related]
9. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
Maiorano BA; De Giorgi U; Verzoni E; Maiello E; Procopio G; Conteduca V; Di Maio M;
Target Oncol; 2024 Jan; 19(1):1-11. PubMed ID: 37993604
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
[TBL] [Abstract][Full Text] [Related]
12. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database.
He Z; Mo J; Jiang W; Zhu J; Yang S; Gao S; Lam K; Li Y; Qiu K; Huang M; Wu J
Int J Gynecol Cancer; 2023 Aug; 33(8):1237-1246. PubMed ID: 37164363
[TBL] [Abstract][Full Text] [Related]
14. Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
Ma Z; Sun X; Zhao Z; Lu W; Guo Q; Wang S; You J; Zhang Y; Liu L
Gynecol Oncol; 2021 Aug; 162(2):496-505. PubMed ID: 34023129
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis.
Chang XF; Ren XL; Yang JQ; Shi JJ; Bai JH; Cui MS; Dong WW
Breast; 2021 Oct; 59():44-50. PubMed ID: 34130011
[TBL] [Abstract][Full Text] [Related]
16. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer.
Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; De Cobelli O; Nolè F
Eur J Cancer; 2015 Sep; 51(14):1970-7. PubMed ID: 26169016
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies.
Santoni M; Conti A; Massari F; Di Nunno V; Faloppi L; Galizia E; Morbiducci J; Piva F; Buti S; Iacovelli R; Ferretti B; Cimadamore A; Scarpelli M; Lopez-Beltran A; Cheng L; Battelli N; Montironi R
Expert Rev Cardiovasc Ther; 2019 Dec; 17(12):917-927. PubMed ID: 31829045
[No Abstract] [Full Text] [Related]
18. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
Liu Y; Meng J; Wang G
Drug Des Devel Ther; 2018; 12():3013-3019. PubMed ID: 30271116
[TBL] [Abstract][Full Text] [Related]
19. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Zhou JX; Feng LJ; Zhang X
Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
